Proactive Investors - Run By Investors For Investors

Biogen ups 2018 profit and revenue guidance after second-quarter earnings and revenue beat expectations

The Nasdaq-listed firm said its earnings for the quarter rose to US$867mln, or US$4.18 per share, up from US$863mln, or US$4.07 per share in the year-earlier period
Biotech trials
Biogen said it now expects 2018 adjusted earnings of US$24.90 to US$25.50 per share, an increase from previous guidance of US$24.20 to US$25.20 per share

Biogen Inc. (NASDAQ:BIIB) saw its shares rise in pre-market New York trading on Tuesday as the biotech company raised its 2018 profit and revenue guidance after seeing second-quarter earnings and revenue beat expectations.

The Nasdaq-listed firm said its earnings for the quarter rose to US$867mln, or US$4.18 per share, up from US$863mln, or US$4.07 per share in the year-earlier period.

The group’s adjusted earnings per share of US$5.80 beat the consensus estimate of US$5.21, while revenue for the second quarter rose to US$3.36bn from US$3.08bn, also above consensus of US$3.25bn.

Biogen Increased its 2018 revenue guidance to a range of about US$13bn to US$13.2bn, up from a previous range of between US$12.7bn to US$13.0bn, and above the consensus of US$12.96bn.

The company also said it now expects 2018 adjusted earnings of US$24.90 to US$25.50 per share, an increase from previous guidance of US$24.20 to US$25.20 per share, and above the consensus for US$23.83 per share.

Biogen also announced that it has acquired two neuromuscular drugs - a pre-clinical product and a drug that is in phase 1a trials - from privately-owned biotechnology company AliveGen Inc. for an upfront payment of US$27.5mln.

The group said AliveGen is also eligible for up to US$535mln in additional milestone payments.

In pre-market trading, Biogen shares were nearly 6% higher at US$397.40.

View full BIIB profile View Profile

Biogen Inc Timeline

Related Articles

Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
Oncoprex
October 18 2018
The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use